38 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
patients /24countries Expanded Access through Jan 2024: Pricing PROMISE Contributions allocated: $2,288,998 U.S. $954,349 Intl. Charitable Giving Committed
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
Access through Jan 2024: Pricing PROMISE Contributions allocated: $2,288,998 U.S. $954,349 Intl. Charitable Giving Committed to never raising
8-K
EX-99.2
r03 chiwbguqnt6k73p1
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
3hdt nzrqar
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.2
xs4 3q4iu7pcryazswr
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
2n4iktgv cu5s
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
v502km
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am
8-K
EX-10.1
lrxydn
1 Aug 22
Departure of Directors or Certain Officers
5:10pm
8-K
EX-10.2
a292tvg1k0cce179u
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am
8-K
EX-10.2
ql0ot9907h pca0gbt
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
EX-10.6
i9mwtj71qowz9id1t9j
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am